title: Accrual of non-melanoma skin cancer in renal-transplant recipients: experience of a Victorian tertiary referral institution.
abstract: BACKGROUND
  Cutaneous carcinogenesis is increased in immunosuppressed organ transplant recipients (OTR). Tumour accrual is a useful measure for the rate of cutaneous carcinogenesis. There are few studies in tumour accrual rates in OTR in Australia.
  
  
  METHODS
  This was a prospective study of renal transplant recipients in a single tertiary referral centre over 5 years (60 months). Outcome measures included tumour accrual, and numbers of skin cancers according to clinical risk factors (age, sex, anatomical location, skin phototype, duration of immunosuppression, history of graft rejection, acitretin use, occupational sun exposure and family history of skin cancer).
  
  
  RESULTS
  A total of 142 patients were included in the study, with a median follow-up duration of 1.9 years. Of these patients, 53 (37%) developed a total of 341 invasive non-melanoma skin cancers (NMSC) (253 squamous cell carcinoma [SCC] and 88 basal cell carcinoma [BCC]) over the study period. Accrual for SCC and BCC were 0.89 SCC/patient per year and 0.31 BCC/patient per year, respectively. The overall NMSC accrual was 1.20 NMSC/patient per year. SCC accrual increased with the duration of immunosuppression. NMSC accrual increased with a history of graft rejection.
  
  
  CONCLUSIONS
  The current study provides prospective, histologically verified and quantitative evidence for the increase of cutaneous carcinogenesis in renal transplant recipients in Victoria, Australia.
authors.affiliation: Skin and Cancer Foundation Inc., Melbourne, Victoria, Australia.
authors.forename: Jonathan C
authors.initials: JC
authors.lastname: Ng
authors.forename: Simon
authors.initials: S
authors.lastname: Cumming
authors.forename: Vivian
authors.initials: V
authors.lastname: Leung
authors.forename: Alvin H
authors.initials: AH
authors.lastname: Chong
mesh_terms: D017255:Acitretin / Q000009:adverse effects; D000328:Adult; D000368:Aged; D002280:Basal Cell Carcinoma / Q000453:epidemiology* / Q000235:genetics; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology* / Q000235:genetics; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007641:Keratolytic Agents / Q000009:adverse effects; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D016273:Occupational Exposure / Q000009:adverse effects*; D011446:Prospective Studies; D012878:Skin Neoplasms / Q000453:epidemiology* / Q000235:genetics; D013472:Sunlight / Q000009:adverse effects; D062606:Tertiary Care Centers; D014739:Victoria / Q000453:epidemiology
chemical_list: D007641:Keratolytic Agents; D017255:Acitretin
keywords: basal cell carcinoma; dermatology; immunosuppression; melanoma; skin cancer; squamous cell carcinoma; transplantation